

Variations in Barrett's Esophagus Screening, Diagnosis, and Management among Experts – Myth or Reality?

Allon Kahn M.D.¹, Prasad G. Iyer M.D.², John Clarke M.D.³, Afrin Kamal M.D.³

¹Division of Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, Arizona; ²Division of Gastroenterology and Heaptology, Mayo Clinic, Rochester, Minnesota; ³Division of Gastroenterology and Hepatology, Stanford University, Redwood City, California

BACKGROUND

- Barrett's esophagus (BE) is the only known precursor to esophageal adenocarcinoma (EAC).
- Although clinical practice guidelines provide an evidence-based framework for BE diagnosis and management, lack of evidence in some areas may preclude definitive recommendations and controversies remain.
- BE experts are best positioned to provide guidance in these areas, but uniformity of their perspectives has not been assessed.

AIM

• We aimed to assess practice patterns specific to BE screening, diagnosis and management among recognized BE expert gastroenterologists.

METHODS

- We surveyed BE expert gastroenterologists (N= 38) throughout the United States.
- The investigator-developed online survey assessed expert beliefs and practice patterns specific to screening, diagnosis, and management of BE.
- We hypothesized practice patterns would vary, particularly in the category of management.

RESULTS

- 34 BE experts (89%) responded to the survey.
- **Table 1** outlines the demographic and practice characteristics of the respondents.
- The results for each question are displayed in the figures that follow.

TABLE 1: SURVEY RESPONDENT CHARACTERISTICS

	Ctudy norticipanto
Characteristic	Study participants (N = 34)
Male sex	29 (85.3%)
Time in practice	
≤10 years 11-20 years	8 (23.5%) 10 (29.4%)
>20 years	16 (47.1%)
Region of practice	
Southwest	13 (38.2%)
Northeast	10 (29.4%)
Midwest	6 (17.7%)
Southeast	3 (8.8%)
Northwest	2 (5.9%)
GI Subspecialty	
Esophagologist – Barrett's esophagus focus	18 (52.9%)
Advanced endoscopist	10 (29.4%)
Esophagologist – GERD/motility	1 (2.9%)
focus	1 (2.9%)
General gastroenterologist	4 (11.8%)
Other	
Subspecialty training	
Advanced endoscopy	16 (47.1%)
Esophageal fellowship	3 (8.8%)
No additional subspecialty training	15 (44.1%)
Practice setting Academic tertiary referral	28 (82.4%)
Academic community hospital	2 (5.9%)
Integrated health system	1 (2.9%)
Private practice (>10 physician)	2 (5.9%)
Private practice (≤10 physician)	1 (2.9%)
Barrett's esophagus patients	
per month	12 (25 20/)
<10	12 (35.3%) 13 (38.2%)
11-20	4 (11.8%)
21-30	5 (14.7%)
>30	- ()
Barrett's esophagus endoscopies	
per month	7 (20.6%)
≤10 11-20	16 (47.1%)
>20	11 (32.4%)
- 20	

©2022Mayo Foundation for Medical Education and Research



GERD MANAGEMENT















POST-TREATMENT SURVEILLANCE



e
e

Refer to a colleague for resection

Piecemeal cap-snare EMR Biopsy and await pathology

Treat with APC< no biopsy Treat with focal RFA, no biops biopsies and treat with focal RF.



SELECTED CLINICAL SCENARIOS



During surveillance EGD for long-segment BE-HGD with complete eradication of intestinal metaplasia, you encounter 2 small (1 cm) islands of columnar epithelium 2 cm above the GEJ. How would you approach management?



CONCLUSIONS

 Despite available clinical practice guidelines, BE experts exhibit substantial variability in practice, particularly with respect to the use of WATS-3D, NDBE ablation, and post-CEIM management.

 These results shed light on continued controversies in BE management and emphasize the need for further research to better define management in these areas.

